Additionally, CDKN2A deletion — which encodes ARF, a p53 stabilizer via MDM2 antagonism — occurs in 30–50% of ALL, providing another means by which p53 function can be abrogated [14, 15]. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.